甘丙肽及其受体亚型在人乳腺癌标本中的表达

目的 探索甘丙肽(galanin,GAL)及其受体亚型(galanin receptor1、2、3, GALR1、2、3)在乳腺癌及癌周组织中的表达情况,分析其与不同临床治疗方法的关系。方法 qRT-PCR法检测乳腺癌及癌周组织的GAL及其3种受体亚型mRNA的表达情况。Western blotting分析GAL在乳腺癌及癌周组织中的表达情况。t检验分析不同术前处理组之间癌组织的GAL及其受体亚型表达的变化,而配对t检验用于分析同一术前处理组内癌组织和癌周组织之间GAL及其受体亚型表达的变化。结果 在术前无治疗组中,癌组织GAL mRNA及GAL蛋白比癌旁组织高(P<0.05,P<0.01),而GALR1、GALR2、GALR3 mRNA比癌旁组织低(P<0.05,P<0.05,P<0.01)。经过新辅助化学治疗(neoadjuvant chemotherapy, NAC)与高强度聚焦超声射频消融术(high intensity focused ultrasound, HIFU)治疗后,癌组织与癌旁组织相比,GAL及其受体mRNA和蛋白差异无统计学意义,但是与术前无治疗组癌组织相比,GAL mRNA及GAL蛋白明显降低(P<0.05)。此外,经过NAC治疗后癌组织中GALR3 mRNA要明显高于术前无治疗组的癌组织(P<0.01)。结论 GAL及其受体亚型在乳腺癌中存在异常表达,并与临床治疗方法有关,可能为乳腺癌的诊断、治疗及预后提供了新的生物学标志。

Expression of galanin and its receptor subtypes in human breast cancer

Objective To determine the expression of galanin(GAL) and galanin receptor 1、2、3 (GALR1、2、3) in breast cancer and the paired peritumoral tissues; To analyze the relationship between the different clinical therapies and the expression of galanin and its receptor subtypes. Methods qRT-PCR was performed to detect the mRNA level of galanin and its three receptor subtypes in breast cancer and the paired peritumoral tissues. Western blotting was carried out to detect the GAL protein level in breast cancer and the paired peritumoral tissues. t-test was used to analyze the expression of galanin and its three receptor subtypes in cancer tissues of different groups; while paired t-test was performed to analyze the expression of galanin and its three receptor subtypes in breast cancer and the paired peritumoral tissues of the same group. Results The GAL mRNA and protein levels of cancer tissues were higher than the paired peritumoral tissues in the group of no preoperative treatment (P<0.05, P<0.01), whereas the mRNA levels of GALR1, GALR2 and GALR3 were lower than the paired peritumoral tissue (P<0.05, P<0.05, P<0.01). In the NAC and HIFU groups, there were no significant differences in GAL protein, GAL and its receptors mRNA levels between the cancer and the paired peritumoral tissues (P<0.05, P<0.05, P<0.01). However, the GAL protein and GAL mRNA levels were lower than the group of no preoperative treatment (P<0.05). In addition, the GALR3 mRNA level was higher than the group of no preoperative treatment in the NAC group (P<0.01). Conclusion The abnormal expression of galanin and its receptor subtypes in breast cancer was relevant to different clinical therapies, which might be used as a potential biomarker for breast cancer diagnosis, therapy and prognosis.